Pharmacyclics agent cleared in U.K.

Article

Pharmacyclics of Sunnyvale, CA, has received regulatory approvalin the U.K. for its Gadolite oral MRI contrast agent, which isindicated for diagnosing pelvic and abdominal disorders. Gadolitewill be marketed in the U.K. and the rest of Europe by E-Z-EMof

Pharmacyclics of Sunnyvale, CA, has received regulatory approvalin the U.K. for its Gadolite oral MRI contrast agent, which isindicated for diagnosing pelvic and abdominal disorders. Gadolitewill be marketed in the U.K. and the rest of Europe by E-Z-EMof Westbury, NY, under a deal between the two companies announcedthis month. E-Z-EM will file marketing applications for Gadolitein additional European countries under the European Union's mutualrecognition process.

E-Z-EM also has rights to Gadolite in the U.S., Canada, andMexico. A new drug application for Gadolite was filed with theFood and Drug Administration in September, according to the companies.Gadolite is manufactured by Glaxo Wellcome.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.